BDBM324370 1-cyclobutyl-N-(8-(2- ((1-methyl-1H-pyrazol- 4-yl)amino)pyrimidin- 4-yl)-2-(oxetan-3-yl)- 2,3,4,5-tetrahydro-1H- benzo[c]azepin-5-yl)- 1H-1,2,3-triazole-4- carboxamide::US10189829, Compound 66::US10227341, Compound 66
SMILES: Cn1cc(Nc2nccc(n2)-c2ccc3C(CCN(Cc3c2)C2COC2)NC(=O)c2cn(nn2)C2CCC2)cn1
InChI Key: InChIKey=RLRYTVUORICEOL-UHFFFAOYSA-N
Data: 2 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324370 (1-cyclobutyl-N-(8-(2- ((1-methyl-1H-pyrazol- 4-yl)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Neuroscience | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | J Med Chem 51: 1730-9 (2008) BindingDB Entry DOI: 10.7270/Q25M681D | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324370 (1-cyclobutyl-N-(8-(2- ((1-methyl-1H-pyrazol- 4-yl)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
BIOGEN MA INC. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US10189829 (2019) BindingDB Entry DOI: 10.7270/Q2V69MP8 | |||||||||||
More data for this Ligand-Target Pair |